Asymmetric synthesis of novel quaternary α-hydroxy-δ-lactam dipeptide surrogates

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 17, 1999, Pages 2625-2628

  Minami, Nathaniel K ^a   Reiner, John E ^a   Semple, J Edward ^a  

^a Dendreon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA LACTAM DERIVATIVE; LACTAM DERIVATIVE;

ARTICLE; CHEMICAL MODIFICATION; CHIRALITY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVE SITE; OXYGENATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

DIPEPTIDES; LACTAMS; PROTEIN STRUCTURE, QUATERNARY;

EID: 0033530116     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00448-5     Document Type: Article

References (35)

1. th birthday.
2. Lactams: (a) Owens, T. D.; Semple, J. E. Bioorg. Med. Chem. Lett. 1998, 8, 3683.
3. (b) Semple, J. E.; Rowley, D. C.; Owens, T. D.; Minami, N. K.; Uong, T.H.; Brunck, T. K. ibid., 3525.
4. (c) Semple, J. E.; Rowley, D. C.; Brunck, T. K.; Ha-Uong, T.; Minami, N. K.; Owens, T. D.; Tamura, S. Y.; Goldman, E. A.; Siev, D. V.; Ardecky, R. J.; Carpenter, S. H.; Ge, Y.; Richard, B. M.; Nolan, T. G.; Håkanson, K.; Tulinsky, A.; Nutt, R. F.; Ripka, W. C. J. Med. Chem. 1996, 39, 4531.
5. Pyridones and related heterocycles: (a) Clive, D. J.; Coltart, D. M; Zhou, Y. J. Org. Chem. 1999, 64, 1447.
6. (b) Reiner, J. E.; Lim-Wilby, M. S. L.; Brunck, T. K.; Uong, T. H.; Goldman, E. A.; Abelman, M. A.; Nutt, R. F.; Semple, J. E.; Tamura, S. Y. Bioorg. Med. Chem. Lett. 1999, 9, 895 and refs. cited therein.
7. Bicyclic and heterobicyclic lactam manifolds: (a) Tamura, S. Y.; Goldman, E. G.; Brunck, T. K.; Ripka, W. C.; Semple, J. E. Bioorg. Med. Chem. Lett. 1997, 7, 331.
8. (b) Review: Hanessian, S.; McNaughton-Smith, G.; Lombart, H.-G.; Lubell, W. D. Tetrahedron 1997, 38, 12789.
9. Quaternary lactams: (a) Semple, J. E.; Minami, N. K.; Tamura, S. Y.; Brunck, T. K.; Nutt, R. F.; Ripka, W. C. Bioorg. Med. Chem. Lett. 1997, 7, 2421.
10. (b) Semple, J. E. Tetrahedron Lett. 1998, 39, 6645.
11. (c) Semple, J. E. Bioorg. Med. Chem. Lett. 1998, 8, 2501.
12. (d) Salimbeni, A.; Paleari, F.; Canevotti, R.; Criscuoli, M.; Lippi, A.; Angiolini, M.; Belvisi, L.; Scolastico, C.; Colombo, L. Bioorg. Med. Chem. Lett. 1997, 7, 2205.
13. Krishnan, R.; Zhang, E.; Hakansson, K.; Arni, R. V.; Tulinsky, A.; Lim-Wilby M. S. L.; Levy, O. E.; Semple, J. E.; Brunck, T. K. Biochemistry 1998, 37, 12094.
14. (a) Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K. S.; Kwong, H. L.; Morikawa, K.; Wang, Z. W.; Xu, D.; Zhang, X.L. J. Org. Chem. 1992, 57, 2768.
15. (b) Shao, H.; Rueter, J. K.; Goodman, M. J. Org. Chem. 1998, 63, 5240.
16. (c) Berrisford, D. J.; Bolm, C.; Sharpless, K. B. Angew. Chem. Int. Ed. Engl. 1995, 34, 1059.
17. (d) Kolb, H. C.; Van Nieuwenhze, M. S.; Sharpless, K. B. Chem. Rev. 1994, 2483.
18. All new compounds were characterized by full spectroscopic (NMR, low/high resolution MS) data. Yields refer to spectroscopically and chromatographically homogenous (≥95% by HPLC, TLC) materials.
19. Flynn, D. L.; Zelle, R.E.; Grieco, P. A. J. Org. Chem. 1983, 48, 2424.
20. (a) Bose, A. K.; Fahey, J. L.; Manhas, M. S. Tetrahedron, 1974, 30, 3.
21. (b) Zimmer, H.; Armbruster, D. C.; Trauth, L. J. J. Heterocycl. Chem. 1965, 2, 171.
22. (c) Alternate multi-step organometallic approach: Campi, E. M.; Chong, J. M.; Jackson, W. R.; Van Der Schoot, M. Tetrahedron, 1994, 50, 2533.
23. The e.e. values reported for the diol adducts 3a-c were determined by chiral HPLC using an analytical Chiracel AD column, eluting with an isopropanol, hexane 40-60% gradient, 0.5 mL/min flow rate. The assignment of absolute stereochemistry follows from application of the Sharpless pneumonic (ref 6a). Furthermore, 4b and 5b were elaborated into active thrombin inhibitors with α-(R)-hydroxy quaternary lactam stereochemistry, which is deemed essential for high potency due to optimal binding at S3 of the thrombin active site (cf. ref 1, 3, and 4).
24. "Fortified" AD-mix is prepared by increasing the catalyst and chiral ligand loading of commercial AD-mix: (a) Walsh, P. J.; Sharpless, K. B. Synlett. 1993, 605.
25. (b) Bennani, Y. L.; Sharpless, K. B. Tetrahedron Lett. 1993, 34, 2079.
26. For AD studies on exocyclic alkylidene lactones and related substrates to generate quaternary α-hydroxy lactone derivatives see: Curran, D. P.; Ko, S. B. J. Org. Chem. 1994, 59, 6139.
27. (a) Gao, Y.; Sharpless. K. B. J. Am. Chem. Soc. 1988, 110, 7538.
28. (b) He. L.; Byun, H. S.; Bittman. R. Tetrahedron Lett. 1998, 39, 2071.
29. (a) Ballestri, M.; Chatgilialoglu, C; Clark, K. B.; Griller, D.; Giese, B.; Kopping, B. J. Org. Chem. 1991, 56, 678.
30. (b) Chatgilialoglu, C.; Ferrerei, C.; Gimisis, T. in Chem. Org. Silicon Compd. Rappoport, Z.; Apeloig, Y., Eds.; Wiley, Chichester. UK, 1998; Vol. 2 (Pt.2), 1539.
31. (a) Evans, D. A.; Nelson, J. V.; Vogel; E.; Taber, T. R. J. Am. Chem. Soc. 1981, 103, 3099 and references cited therein.
32. (b) Evans, D. A.; Nelson, J. V.; Taber. T. R. Top. Stereochem. 1982, 13, 1.
33. (c) Heathcock, C. H. In Asymmetric Synthesis, Morrison, J. D., Ed.; Academic: New York, 1983; Vol. 2, Ch. 2.
34. (a) Kawashima, E.; Uchida, S.; Miyahara, M.; Ishido, Y. Tetrahedron Lett. 1997, 38, 7369.
35. (b) Apeloig, Y.; Nakash, M. J. Am. Chem. Soc. 1994, 116, 10781.